iPSirius appoints COO to oversee human trials with allogeneic cancer vaccines made from stem cells
Paris, France, 10th February 2023 – iPSirius, a pre-clinical biotech company in the immuno-oncology field, is pleased to announce the appointment of a new COO, Dr. Stephen Sullivan. Dr. Sullivan, previously the program manager at the Global Alliance for iPSC therapies, is a pluripotent stem cell manufacturing expert. He will oversee the day-to-day operations of the company and the first in-human trials for the company’snovel therapeutic, IPVAC. [Read more…]